FDA advisors recommend Eli Lilly’s Alzheimer’s drug donanemab, paving way for approval
If approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.
If approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.
Comments are closed.